Seoul Pharma Co., Ltd (KOSDAQ:018680)

Seoul Pharma Statistics

Total Valuation

Seoul Pharma has a market cap or net worth of KRW 35.68 billion. The enterprise value is 43.22 billion.

Market Cap	35.68B
Enterprise Value	43.22B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Seoul Pharma has 11.66 million shares outstanding.

Current Share Class	11.66M
Shares Outstanding	11.66M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	4.73M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.68
PB Ratio	0.92
P/TBV Ratio	0.94
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 18.62, with an EV/FCF ratio of -10.04.

EV / Earnings	-65.40
EV / Sales	0.83
EV / EBITDA	18.62
EV / EBIT	n/a
EV / FCF	-10.04

Financial Position

The company has a current ratio of 1.99, with a Debt / Equity ratio of 0.46.

Current Ratio	1.99
Quick Ratio	1.04
Debt / Equity	0.46
Debt / EBITDA	7.71
Debt / FCF	-4.16
Interest Coverage	-0.75

Financial Efficiency

Return on equity (ROE) is -1.69% and return on invested capital (ROIC) is -0.38%.

Return on Equity (ROE)	-1.69%
Return on Assets (ROA)	-0.29%
Return on Invested Capital (ROIC)	-0.38%
Return on Capital Employed (ROCE)	-0.59%
Revenue Per Employee	303.46M
Profits Per Employee	-3.84M
Employee Count	172
Asset Turnover	0.74
Inventory Turnover	1.58

Taxes

Income Tax	-84.70M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -21.20% in the last 52 weeks. The beta is 0.55, so Seoul Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.55
52-Week Price Change	-21.20%
50-Day Moving Average	3,218.70
200-Day Moving Average	3,331.35
Relative Strength Index (RSI)	45.41
Average Volume (20 Days)	8,367

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Seoul Pharma had revenue of KRW 52.20 billion and -660.90 million in losses. Loss per share was -56.68.

Revenue	52.20B
Gross Profit	31.83B
Operating Income	-329.39M
Pretax Income	-745.60M
Net Income	-660.90M
EBITDA	2.32B
EBIT	-329.39M
Loss Per Share	-56.68

Balance Sheet

The company has 10.36 billion in cash and 17.90 billion in debt, giving a net cash position of -7.54 billion or -646.88 per share.

Cash & Cash Equivalents	10.36B
Total Debt	17.90B
Net Cash	-7.54B
Net Cash Per Share	-646.88
Equity (Book Value)	38.68B
Book Value Per Share	3,317.27
Working Capital	17.18B

Cash Flow

In the last 12 months, operating cash flow was -2.98 billion and capital expenditures -1.32 billion, giving a free cash flow of -4.31 billion.

Operating Cash Flow	-2.98B
Capital Expenditures	-1.32B
Free Cash Flow	-4.31B
FCF Per Share	-369.24

Margins

Gross margin is 60.98%, with operating and profit margins of -0.63% and -1.27%.

Gross Margin	60.98%
Operating Margin	-0.63%
Pretax Margin	-1.43%
Profit Margin	-1.27%
EBITDA Margin	4.45%
EBIT Margin	-0.63%
FCF Margin	n/a

Dividends & Yields

Seoul Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-1.85%
FCF Yield	-12.07%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on April 12, 2004. It was a forward split with a ratio of 2.

Last Split Date	Apr 12, 2004
Split Type	Forward
Split Ratio	2

Scores

Seoul Pharma has an Altman Z-Score of 1.78 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.78
Piotroski F-Score	1